<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633983</url>
  </required_header>
  <id_info>
    <org_study_id>khateb-HMO-CTIL</org_study_id>
    <nct_id>NCT01633983</nct_id>
  </id_info>
  <brief_title>Methotrexate for Central Serous Chorioretinopathy Treatment Trial</brief_title>
  <acronym>MTX4CSC</acronym>
  <official_title>Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Averbukh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple
      reports have indicated correlation of appearance of CSC with exposure to exogenous or
      elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids
      is upregulated in many inflammatory conditions, control of the inflammation may be beneficial
      in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX) is widely
      used to control different types of inflammation. The investigators are going to try an
      escalating doses of MTX to treat CSC under full medical supervision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the
      center of the macula in adults of working age. Though previously the condition was considered
      stress-related, multiple recent reports have indicated correlation of appearance of CSC with
      exposure to exogenous or elevated levels of endogenous corticosteroid. Since the level of
      endogenous corticosteroids is upregulated in many inflammatory conditions, control of the
      inflammation may downregulate the endogenous steroids thus eliminating the stimulus for CSC.
      Methotrexate (MTX) is widely used to control different types of inflammation. Few short
      retrospective series of beneficial effect of MTX on CSC were reported recently. The
      investigators are going to try an escalating doses of MTX to treat CSC under full medical
      supervision in a prospective manner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optical Coherence Tomography indicating the level of central serous detachment</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic CSC will be given an immediate MTX treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>7.5 mg per week p.o. escalating up to 15 mg per week</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delayed treatment</intervention_name>
    <description>Methotrexate 7.5 mg per week per os escalating to 15 mg per week</description>
    <arm_group_label>Delayed treatment</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Observation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Central Serous Chorioretinopathy

        Exclusion Criteria:

          -  Pregnancy

          -  Liver disease

          -  Kidney disease

          -  Steroid use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Averbukh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Hebrew Univercity Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edward Averbukh, MD</last_name>
      <phone>+972-508946140</phone>
      <email>edwaver@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Samer Khateb, MD, PhD</last_name>
      <phone>+972-542504857</phone>
      <email>samerkhateb@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samer Khateb, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>July 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Edward Averbukh</investigator_full_name>
    <investigator_title>Head of Hadassah Mt Scopus Ophthalmology Center</investigator_title>
  </responsible_party>
  <keyword>Central Serous Chorioretinopathy</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

